Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.

Bioorganic & medicinal chemistry - 1 Dec 2020

Sun Minghao, Cai Shi, Li Pei, Zhang Fangqing, Zhang Huibin, Zhou Jinpei

Abstract excerpt

'precision medicine' is characterized by the selection of targeted drugs based on genetic characteristics of tumor from patients, and no longer selected basis on the type of cancer tissue. Among them, clinical trials on neurotrophin receptor tyrosine kinase genes (NTRK) have proven that great anti-cancer effects can be achieved in different cancer patients. In this paper, a novel total of twenty compounds in two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Cell Line, Tumor
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Receptor, trkA

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 33069129
DOI: 10.1016/j.bmc.2020.115811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.PMID 33069129Read ↗

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.Semantic proximity Read ↗

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read ↗

Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.Semantic proximity Read ↗

Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insightsSemantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer TreatmentSemantic proximity Read ↗

Receptor tyrosine kinases as targets for anticancer drugs.Semantic proximity Read ↗

Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.Semantic proximity Read ↗

Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.Semantic proximity Read ↗

Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-d]pyrimidine derivatives as new EGFR inhibitors.Semantic proximity Read ↗

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.Semantic proximity Read ↗

Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.